Nick de Jonge
YOU?
Author Swipe
View article: Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity
Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity Open
Purpose Haematology patients with high-risk neutropenia are prone to mucosal-barrier injury-associated laboratory-confirmed bloodstream infections (MBI-LCBI). We assessed risk factors for MBI-LCBI including candidaemia in neutropenic haema…
View article: Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium Open
Histiocytic disorders are rare hematologic neoplasms characterized by a notable dependence on mitogen-activated protein kinase signaling. Targeted therapy is an emerging treatment option, yet the number of reported patients remains limited…
View article: The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey Open
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospita…
View article: Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study
Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study Open
Background To date, azoles represent the only viable option for oral treatment of invasive Candida infections, while rates of azole resistance among non-albicans Candida spp. continue to increase. The objective of this sub-analysis of the …
View article: P1530: CORTICOSTEROIDS FOR INFLAMMATORY RESPONSES DURING INDUCTION CHEMOTHERAPY IN MYELOID MALIGNANCIES ARE NOT ASSOCIATED WITH INCREASED INCIDENCE OF INVASIVE FUNGAL INFECTIONS
P1530: CORTICOSTEROIDS FOR INFLAMMATORY RESPONSES DURING INDUCTION CHEMOTHERAPY IN MYELOID MALIGNANCIES ARE NOT ASSOCIATED WITH INCREASED INCIDENCE OF INVASIVE FUNGAL INFECTIONS Open
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Corticosteroids have been acknowledged to increase the risk of invasive fungal infections (IFIs). Its use during remission-induction chemotherapy for myeloid m…
View article: S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY
S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY Open
Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatr…
View article: P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT
P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT Open
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: There is a lack of consolidated data has resulted in a general skepticism on anti-SARS-CoV-2 fourth dose efficacy. As a consequence, only few individuals recei…
View article: Clinical Impact of Polymerase Chain Reaction–Based <i>Aspergillus</i> and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study
Clinical Impact of Polymerase Chain Reaction–Based <i>Aspergillus</i> and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study Open
Background Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy. Methods In a prospective study…
View article: Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry Open
Background The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for morta…
View article: Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes life-threatening COVID-19 in hematologic malignancy (HM) patients, associated with high morbidity and mortality in this particularly vulnerable population.1 After more tha…
View article: B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA) Open
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (C…
View article: Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey Open
International audience
View article: Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey Open
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccin…
View article: Outcome of infection with omicron <scp>SARS‐CoV</scp>‐2 variant in patients with hematological malignancies: An <scp>EPICOVIDEHA</scp> survey report
Outcome of infection with omicron <span>SARS‐CoV</span>‐2 variant in patients with hematological malignancies: An <span>EPICOVIDEHA</span> survey report Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM).1 The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutati…
View article: Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; the value of a surveillance-culture-guided empirical therapy approach
Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; the value of a surveillance-culture-guided empirical therapy approach Open
Objectives Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative pathogens to third-generation cephalosporins is increasing. We aimed to pro…
View article: COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) Open
Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML pati…
View article: Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study
Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study Open
Objectives Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative pathogens to third-generation cephalosporins is increasing. We aimed to ass…
View article: Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy and rationale for surveillance- culture-guided empirical therapy; results from an 11-year multi-centre retrospective study
Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy and rationale for surveillance- culture-guided empirical therapy; results from an 11-year multi-centre retrospective study Open
Objectives Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative pathogens to third-generation cephalosporins is increasing. We aimed to pro…
View article: COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) Open
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML …